UKPDS study finds early blood sugar control with insulin, sulfonylureas, or metformin reduces deaths, heart attacks, and complications in type 2 diabetes patients.

UKPDS study, one of the longest type 2 diabetes trials, shows early blood sugar control with insulin, sulfonylureas, or metformin reduces deaths by 10%, heart attacks by 17%, and diabetic complications by 26%. Metformin specifically reduces heart attacks by 31% and deaths by 20%. Early detection and intensive treatment of type 2 diabetes are essential for improved patient outcomes and life expectancy.